Key result
Eprosartan-based therapy for 6 months in hypertensive patients was associated with significant blood pressure reduction and a 1-point increase in mean MMSE score from baseline.
Why the study?
Does eprosartan-based therapy improve cognitive function and reduce blood pressure in patients aged ≥ 50 years with essential hypertension?
Observational (n=853)
Open-label
Yes
Does eprosartan-based therapy improve cognitive function and reduce blood pressure in patients aged ≥ 50 years with essential hypertension?
Eprosartan-based antihypertensive therapy significantly reduces blood pressure and may preserve or improve cognitive function in older patients with essential hypertension.
Answers are grounded in this paper and cite their sources.
Eprosartan may support cognitive preservation alongside BP control in older hypertensives; leaves open randomized confirmation.
BACKGROUND: Studies have indicated a relationship between hypertension and cognitive function. The possible effect of antihypertensive therapy on cognitive disorders is therefore a matter of interest. MATERIALS AND METHODS: The Observational Study on Cognitive function And SBP Reduction (OSCAR) was an open-label, multinational trial designed to evaluate the impact of eprosartan-based antihypertensive therapy on cognitive function in patients with essential hypertension. Eprosartan 600 mg/day for 6 months (with provision for additional medication as needed) was initiated in hypertensive subjects aged ≥ 50 years. A total of 853 patients in an intention-to-treat cohort from seven countries of the Middle East was identified for subgroup analysis. RESULTS: Arterial blood pressure was reduced significantly (P < 0.001) during the study: At the end of 6 months of eprosartan-based therapy, the mean (±SD) reduction from baseline was 32.1 ± 14.3/14.6.3 ± 8.6 mmHg (P < 0.001). Mean pulse pressure was reduced by 18.3 ± 13.1 mmHg (P < 0.0001 vs baseline). Blood pressure was normalized (systolic <140 mmHg and diastolic <90 mmHg) in 68.2% of patients. The overall mean Mini-Mental State Examination (MMSE) score after 6 months of eprosartan-based therapy was one-point higher than at baseline (P < 0.001). MMSE score on completion of 6 months' follow-up was either unchanged or increased from baseline in 793 (93%) individuals and decreased in 60 (7%). Factors associated with stability of or improvement in cognitive function included MMSE score at baseline, diastolic blood pressure (DBP) at baseline, and treatment-induced change in DBP. CONCLUSION: Results from the Middle East subgroup of OSCAR are supportive of the hypothesis that antihypertensive therapy based on angiotensin-receptor blocker therapy with eprosartan may be associated with preservation or improvement of cognitive function.
No takes yet. Share an insight, caveat, or question.
Radaideh et al. (2011) conducted an observational in Essential hypertension (n=853). Eprosartan-based antihypertensive therapy was evaluated on Mini-Mental State Examination (MMSE) score (1-point increase, p=<0.001). Eprosartan-based therapy for 6 months in hypertensive patients was associated with significant blood pressure reduction and a 1-point increase in mean MMSE score from baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: